US Recalls Vyvanse Due to Efficacy Concerns

The U.S. Food and Drug Administration (FDA) has announced the recall of multiple lots of Vyvanse, known chemically as lisdexamfetamine dimesylate, which is commonly prescribed for attention deficit hyperactivity disorder (ADHD). This action follows quality control tests indicating that the medication may not meet the required efficacy standards.

The California Board of Pharmacy reported that the medication failed a dissolution test, a critical assessment that ensures the active ingredient is properly absorbed in the body. The board noted that the non-compliant capsules "may not deliver the optimal therapeutic dose, potentially leading to reduced effectiveness for patients."

Health authorities have confirmed that this issue does not pose an immediate health risk, but it could hinder patients from achieving the full therapeutic benefits of the medication. The recall affects several dosages, including 10, 20, 30, 40, 50, 60, and 70 mg.

ADHD is a behavioral disorder that impacts concentration, activity levels, and impulse control, often diagnosed in children but also present in adults. Vyvanse is one of the most frequently prescribed medications for this condition, with over 9 million prescriptions issued in 2023.

Authorities recommend that patients with affected bottles contact their healthcare providers or pharmacies to exchange the medication or obtain a refund.